- Lymphovascular invasion (LVI) predicts poorer 5-year OS in patients with hormone-receptor (HR)-positive early breast cancer (eBC) with intermediate recurrence scores on multigene Oncotype DX (ODX) molecular profiling.
- LVI does not affect 5-year OS in patients with low- or high-risk ODX scores.
Why this matters
- Patients with intermediate ODX scores are more frequently foregoing chemotherapy.
- The results of this study, if confirmed by others, suggest clinicians should counsel patients with intermediate ODX scores not to forego chemotherapy.
- Retrospective cohort (n=657) HR+ eBC patients who underwent testing for LVI and ODX.
- Funding: None disclosed.
- Median follow-up was 61.3 months.
- LVI was found in 6% of cohort.
- LVI+ (vs LVI−) was not associated with ODX scores (P=.225).
- LVI+ (vs LVI−) patients had worse 5-year DFS (HR, 2.93; P=.04).
- LVI+ (vs LVI−) patients had worse 5-year OS if they had intermediate ODX scores (99% vs 100%, respectively; P=.04), but not if they had high or low ODX scores.
- Retrospective design.
- Small number of LVI+ patients.